The breakthrough combines a biomaterial – a substance that has been engineered to interact with biological systems for a medical purpose – and ‘logic gates’ – a simple mathematical principle underpinning basic programming commands in […]
TiGenix (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, announces today that the 52-week […]
Medical Prognosis Institute (MPI.ST) spinout Oncology Venture (OV:ST) announces: As previously announced to the market on December 14, 2017, Oncology Venture hereby disclose the initial conclusion from a study of the DRP of a phase […]
The first half of 2018 will be pivotal for Bay Area-based Rigel Pharmaceuticals, Inc. as the company awaits regulatory approval for its rare blood disorder drug and builds out the internal infrastructure to commercialize the product. […]
Renova Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that it will present an overview of its RT-100 AC6 gene transfer Phase 3 clinical trial in a […]